MedTrace Logo

ASPIrin in Reducing Events in Dialysis ( ASPIRED )

NCT04381143 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 9000

Last updated 2025-11-18

No results posted yet for this study

Summary

People with kidney failure requiring dialysis have a much higher risk of developing cardiovascular (CV) disease compared with the general population. A cardiac cause accounts for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time, this population has increased risks of clotting as well as bleeding episodes. While aspirin is known to reduce cardiovascular complications in the general population, evidence to support the use of aspirin in people with ESKD receiving dialysis therapy is currently lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin use in dialysis patients safely improves outcomes compared with no aspirin use.

Conditions

  • CKD (Chronic Kidney Disease) Stage 5D

Interventions

DRUG

Aspirin 100 mg Oral Tablet

Aspirin 100 mg tablet daily

DRUG

Matching Placebo

Matching Placebo 1 pill daily

Sponsors & Collaborators

  • The George Institute

    collaborator OTHER

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Xueqing Yu · Guangdong Provincial People's Hospital

  • Vlado Perkovic · The University of New South Wales Sydney

  • Muh Geot Wong · The George Institute

  • Wei Chen · First Affiliated Hospital, Sun Yat-Sen University

  • Li Fan · Guangdong Provincial People's Hospital

  • Zhiming Ye · Guangdong Provincial People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-30
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04381143 on ClinicalTrials.gov